Pribylová O, Petruzelka L, Honová H, Fischer J, Bustová I, Siffnerová H, Kůta M, Miller V, Hacklová M, Machácek J, Kohoutek M, Vodvárka P, Kyselá T, Tajblová J, Suk J, Dorazilová V, Bauer J
Onkologická klinika Vseobecné fakultní nemocnice v Praze a 1. lékarské fakulty Univerzity Karlovy, Praha.
Sb Lek. 1998;99(1):25-31.
The aim of this multicentric, prospective randomized trial is to evaluate and to compare, effects and toxicities of two chemotherapeutic combinations (AC and CMF) in adjuvant treatment of breast cancer. Both combinations were given in equitoxic doses and number of cycles was only four. There are 106 women treated for breast cancer T1c-3a, N0-1, M0 in the study. After surgery the patients were randomized, 54 for AC combination and 52 for CMF. We evaluate toxicity of this treatment in all patients in the study. Hematological and nonhematological side effects were comparable in both groups except alopecia (in the group AC was 100%). The study is not finished yet. Preliminary analysis does not show any difference between these two groups.
这项多中心前瞻性随机试验的目的是评估和比较两种化疗方案（AC和CMF）在乳腺癌辅助治疗中的疗效和毒性。两种方案的给药剂量等效毒性，且疗程均仅为四个周期。该研究纳入了106例T1c - 3a期、N0 - 1期、M0期乳腺癌女性患者。术后患者被随机分组，54例接受AC方案，52例接受CMF方案。我们评估了研究中所有患者的这种治疗毒性。除脱发外（AC组脱发率为100%），两组的血液学和非血液学副作用相当。该研究尚未结束。初步分析未显示这两组之间存在任何差异。
